RT Journal Article
SR Electronic
T1 Serological detection of SARS-CoV-2 IgG using commercially available immunoassays on dried blood spots collected from patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.11.21261877
DO 10.1101/2021.08.11.21261877
A1 Walker, Gregory J
A1 Davis, Rebecca
A1 Naing, Zin
A1 McEntee, Brad
A1 Lu, Yonghui
A1 Denadija, Tatijana
A1 Rawlinson, William D
YR 2021
UL http://medrxiv.org/content/early/2021/08/16/2021.08.11.21261877.abstract
AB Serological testing for SARS-CoV-2 antibodies provides important research and diagnostic information relating to COVID-19 immune response and surveillance. A major challenge when addressing protection post-infection or vaccination is the difficulty of specimen collection from infants and children. Dried blood spots (DBS) collected by finger prick or heel prick are a minimally invasive sample collection alternative previously used to detect antibodies to other viruses. In this study we evaluated DBS for the detection of SARS-CoV-2 antibodies on three commercially available enzyme (EIA) and chemiluminescent (CLIA) immunoassays by analysing paired DBS and serum samples collected from 54 subjects. We demonstrate that testing of DBS samples was highly sensitive and specific, and quantitative results strongly correlated with those of paired serum. These results suggest that DBS derived blood is a viable alternative to plasma or serum for use in EIAs and CLIAs, and has particular utility as a minimally invasive collection tool for COVID-19 serological testing of infants and children.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding to declareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ETHICS AND GOVERNANCE Office Royal Prince Alfred Hospital QA2021/003All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon contacting the authors